What Is REBYOTA^™?

Learn about REBYOTA and how it helps prevent the recurrence of C. diff infection.

REBYOTA is the first and only FDA approved microbiome-based treatment to prevent recurrent C. diff infection, after you’ve already taken antibiotics¹

Learn more about REBYOTA—access Frequently Asked Questions here.

One dose one visit

This is Freda’s Story

I just knew that if I had C. diff again, I wasn’t going to survive. But my C. diff didn’t come back after I had my treatment.

Watch Freda’s Story

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.

For more information, please talk to your doctor and see full Prescribing Information. Freda was compensated for her time. Individual results may vary.

Image of Freda, clinical study patient — Freda, Clinical Study Patient

Learn more about C. diff infection and preventing its recurrence with REBYOTA.

Download Brochure

In a major clinical study with REBYOTA^1,a:

REBYOTA +
Antibiotics

71%

success rate^1,b

Antibiotics
Alone

58%

success rate^1,b

Of those patients who saw success with REBYOTA^b…

~90% stayed free of C. diff at 6 months.²

Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).¹
In clinical studies, there were no serious adverse events related to REBYOTA.¹

^aThe study was conducted in approximately 300 adult patients with recurrent C. diff infection for up to 8 weeks to find out how well REBYOTA
prevented recurrent C. diff infection. Patients in this study first completed treatment with antibiotics.^1,2^bSuccess rate indicates no other recurrence of C. diff infection at 8 weeks.²

If you’re ready to talk to a doctor, this customized discussion guide is a great way to prepare.

Build Your Guide

Sign up for more information

Receive additional information and resources to help you through your C. diff infection journey.

First Name*(Required)

Last Name*(Required)

Email Address*(Required)

Phone Number

What’s your experience with C. diff infection?*(Required)

What’s your experience with C. diff infection?*

I currently have a C. diff infection

I had a C. diff infection within the last year

I am a C. diff patient caregiver

I’m interested in learning more about C. diff

*Required field.

Consent(Required)

I CONSENT(Required)

By providing the information requested, I am giving Ferring permission to store and use the information that I have provided. I understand and agree that my information will be used by Ferring (or companies working on Ferring’s behalf) to contact me by telephone, email, or mail to provide me with information that may be of interest to me or to invite me to participate in research, educational, and marketing initiatives. I understand that my information will be treated as described in Ferring’s Privacy Notice, which provides details about my privacy rights. Also, I understand that I may opt out of the database at any time by making the request at Data Subject Form or by calling 1-888-FERRING, Monday through Friday, 8 _AM to 7 _PM ET to speak to a representative or leave a voicemail. This statement may be updated from time to time.

References

REBYOTA. Prescribing Information. Parsippany, NJ: Ferring Pharmaceuticals Inc; 2022.
Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double blind, placebo controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527-1538.

Please see Important Safety Information and full Prescribing Information

INDICATION

REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals
18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.

Important Safety Information

You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
You should report to your doctor any infection you think you may have acquired after administration.
REBYOTA may contain food allergens.
Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
REBYOTA has not been studied in patients below 18 years of age.
Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.

Please click to see the full Prescribing Information

What Is REBYOTA™?

REBYOTA is the first and only FDA approved microbiome-based treatment to prevent recurrent C. diff infection, after you’ve already taken antibiotics1

Learn more about REBYOTA—access Frequently Asked Questions here.

Learn more about C. diff infection and preventing its recurrence with REBYOTA.

In a major clinical study with REBYOTA1,a:

REBYOTA + Antibiotics

71%

success rate1,b

Antibiotics Alone

58%

success rate1,b

Of those patients who saw success with REBYOTAb…

~90% stayed free of C. diff at 6 months.2

If you’re ready to talk to a doctor, this customized discussion guide is a great way to prepare.

Sign up for more information

References

Please see Important Safety Information and full Prescribing Information

INDICATION

Important Safety Information

You are leaving REBYOTA.com

What Is REBYOTA^™?

REBYOTA is the first and only FDA approved microbiome-based treatment to prevent recurrent C. diff infection, after you’ve already taken antibiotics¹

In a major clinical study with REBYOTA^1,a:

REBYOTA +
Antibiotics

success rate^1,b

Antibiotics
Alone

success rate^1,b

Of those patients who saw success with REBYOTA^b…

~90% stayed free of C. diff at 6 months.²